Neuroprotective Effect of *Metaplexis japonica* against *in vitro* Ischemia Model

1Nirmala Jamarkattel-Pandit, 2Hocheol Kim
1School of Health and Allied Sciences, Faculty of Science and Technology, Pokhara University, Nepal
2Department of Herbal Pharmacology, College of Oriental Medicine, KyungHee University, Seoul, Korea

**ABSTRACT**

*Metaplexis japonica* (Apocynaceae) is a perennial herb, extensively used in traditional medicinal system for various diseases. The purpose of the study was to evaluate the protective effect of *M. japonica* against *in vitro* ischemia. In the present study, 70% ethanol extract of *M. japonica* was fractionated with different polarity solvents. For *in vitro* ischemia, oxygen-glucose deprivation followed by reoxygenation (OGD-R) in cells was used to investigate the effects of *M. japonica* and its fractions. For oxidative stress model, Hydrogen peroxide (H$_2$O$_2$) induced cell death was studied in HT22 cell line. *M. japonica* and its fractions significantly reduced the HT22 cell damage, which was induced by 4 hrs of OGD followed by 24 hrs of reoxygenation and 24 hrs of H$_2$O$_2$, respectively. The effectiveness of ethyl acetate fraction was higher than other fractions/crude extract. Our results suggest that *M. japonica* could be a neuroprotective agent for the treatment of stroke.

**Key words:** Metaplexis japonica, Stroke, Oxygen-glucose deprivation, Neuroprotection

**Corresponding address:** Nirmala Jamarkattel-Pandit, PhD, School of Health and Allied Sciences, Pokhara University, Nepal. E-mail: nirmalajk@hotmail.com

**INTRODUCTION**

Stroke is a leading cause of death and major disability, which can be due to the ischemic caused by thrombosis or embolism or due to a hemorrhage.1,2 The major disabilities that results from a stroke are cerebral paralysis, cognitive deficits, speech problems, emotional difficulties, daily living problems, and pain.3,4 Stroke triggers many processes, including release of excitatory amino acids, reactive oxygen species (ROS) and inflammatory cytokines and then caused brain edema and damage.5,6 Mainly, two approaches have been developed in ischemic stroke. First approach is to reperfuse by dissolution of the clot with thrombolytic drugs. But these drugs have limitation because these drugs are most effective if administered immediately within 3 hrs of onset. The second approach is to protect the neuronal cell death by interfere with the biochemical cascade of events with neuroprotective agents.7,8 For the this approach, calcium antagonists, NMDA antagonists, glutamate release inhibitors, free radical scavengers, anti-inflammatory agents and leukocyte adhesion inhibitors are being studied.7,8 Many neuroprotective agents, despite proving effective in animal models of stroke, they have been failed in clinical trials because of the toxicity, ineffectiveness etc. Recently many researchers have been focused on natural products for the development of neuroprotective agents because the herbal drugs are regarded to have a relatively higher therapeutic window, fewer side-effects and are economic than synthetic drugs.7 The importance of plant derived material in present day therapy cannot be under estimated. The studies on pharmacological activity of natural compounds/plant extracts present a unique challenge to strike new sources of medicine. Since such useful compounds/plant extracts such as catechins/green tea polyphenols, ginsenoside/Panax ginseng, EGB 761/ginkgo biloba, curcumin/Curcuma longa, baicalein and wogonin/Scutellaria baicalensis, resveratrol/grape, melatonin etc and many others exhibit a broad range of pharmacological activities including neuroprotection.7,9 Therefore, various medicinal plants which are used in Eastern medicine (Ayurveda, Korean and Chinese Traditional medicine), were collected from China, Korea and Nepal and were screened out against oxygen-glucose deprivation followed by reoxygenation (OGD-R), a well accepted *in vitro* ischemia model in rat hippocampus cell line (HT22 cells).10 Among the plant material studied the extract of *Metaplexis japonica* showed the most effective protective activity against ischemia model. Further, *M. japonica* was extracted with 70% EtOH, then fractionated by different polarity solvent and treated against *in vitro* ischemia model. For oxidative stress model, Hydrogen peroxide (H$_2$O$_2$) induced cell death was studied in HT22 cell line. Total phenol, flavonoid and antioxidative activity of *M. japonica* extract and its fractions was also measured to correlate the findings.

**MATERIALS AND METHODS**

**Chemicals and plant materials:** Dulbecco’s Modified Eagle’s Medium (DMEM), lipopolysaccharide (LPS, *Escherichia coli* 0127:138), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), griess reagent, hydrogen peroxide (H$_2$O$_2$), were purchased from Sigma-Aldrich (USA); Fetal Bovine Serum (FBS) was from Hyclone (USA), Penicillin and Streptomycin were obtained from Gibco BRL (USA). All other chemicals used were analytical grade and obtained from either Sigma-Aldrich or Merck. The plants listed in Table 1 were collected from China, Korea and Nepal. The samples were identified
Neuroprotective Effect of Metaplexis japonica against..... JHAS, 2013, Vol. 3, No. 1 P 51-55

by Professor Hoyoung Choi and voucher specimens were deposited at the Department of Herbal Pharmacology, College of Oriental Medicine, Kyung Hee University, Seoul, Korea.

Extraction of plant materials and screening against in vitro model of ischemia: Hundred gram of each herb were extracted with 70% (v/v) ethanol (EtOH) by using reflux apparatus for 3 hrs at 80°C. The extracts were evaporated on a rotary evaporator under reduced pressure to remove organic solvent and then lyophilized to determine the yield. The name of samples, parts used, and yield of extracts are shown in Table 1. For in vitro ischemia model, samples were prepared in DMSO. Final DMSO concentration didn’t exceeded 0.1% (v/v) in all treatment. Hippocampus cells (HT22) and microglia cells (BV2) were obtained from Medical department of Kyung Hee University and maintained at 37°C in a humidified atmosphere containing 5% CO₂. HT22 cells were seeded at a density 1.5 × 10⁵ cells/well and BV2 cells were seeded at a density 5 × 10⁴ cells/well then cultured at 37°C in DMEM supplement with 10% heat-inactivated FBS, penicillin (1 × 10⁵ unit/L), streptomycin (100 mg/L) in a 5% CO₂ incubator. For oxygen- glucose deprivation followed by re-oxygenation (OGD-R), HT22 cells were washed with phosphate buffered saline (pH 7.2) then with glucose free DMEM. The cultures were placed in fresh glucose free DMEM and kept in hypoxic chamber (Forma Scientific, Ohio, USA) containing 95% N₂ and 5% CO₂ at 37°C for 4 hrs. At the end of the exposure period, glucose solution was added, and the cells were incubate in the 5% CO₂ incubator at 37°C for an additional 24 hrs. Samples (10 µg/mL) were treated 30 min before and during 4 hrs OGD exposure. Control plate was treated with the equal amounts of serum free glucose free DMEM and kept in the 5% CO₂ incubator. Nitric oxide (NO) inhibitory activity of each extract was performed according to our previous experiment. Cells were incubated for 24 hrs with or without 1 µg/mL of LPS, in the absence or presence of extract. The NO concentration was measured using the supernatant from the BV2 cells mixing with equal amount of Griess reagent. The optical density (OD) was measured on plate reader (SPECTRA max, USA) at 540 nm. Standard NaNO₃ was used for the calibration curve. Curcumin, a strong antioxidant and anti-inflammatory compound, was used as a reference for NO inhibitory assay.

Extraction and fractionation of M. japonica: The aerial part of M. japonica (1.6 kg) was extracted with 16 L, 70% (v/v) ethanol (EtOH) by using reflux apparatus for 3 hrs at 80°C. The extract was filtered and evaporated with a rotary evaporator (Eyela, Japan) under reduced pressure to remove organic solvent until 1 L. For the crude extract (MJC), about 100 ml was lyophilized until dryness. Remaining aqueous solution was successively partitioned with hexane (MJHf), ethyl acetate (MJEf), and butanol (MJBe), respectively.

**Table 1: Name of plants, using parts and extracts yield**

| S.N. | Sample Name           | Collected From | Parts used | Extract yield (%) |
|------|-----------------------|----------------|------------|-------------------|
| 1    | Achyranthes bidentata | Korea          | leaf       | 41.0              |
| 2    | Acorus calamus        | Nepal          | fruit      | 19.2              |
| 3    | Alisma canaliculatum  | Korea          | root+stem  | 21.4              |
| 4    | Amomum suvatum        | Nepal          | fruit      | 13.0              |
| 5    | Anethum graveolens    | Korea          | seed       | 3.2               |
| 6    | Bambusa textilis      | China          | root       | 0.3               |
| 7    | Cibotium barometz     | Korea          | root       | 12.4              |
| 8    | Clematis chinensis    | China          | root       | 19.9              |
| 9    | Dimocarpus longan     | China          | fruit      | 56.6              |
| 10   | Duchesnea indica      | Korea          | leaf       | 14.8              |
| 11   | Emblica officinalis   | Nepal          | root       | 50.1              |
| 12   | Erycibe obtusifolia   | Korea          | leaf       | 8.8               |
| 13   | Foeniculum vulgare    | Nepal          | fruit      | 10.4              |
| 14   | Gleditsia sinensis    | Korea          | fruit      | 21.4              |
| 15   | Glycyrrhyza globra    | Nepal          | stem       | 28.2              |
| 16   | Leonurus sibiricus    | Korea          | seed       | 5.9               |
| 17   | Liquidambar formosana | Korea          | fruit      | 3.7               |
| 18   | Metaplexis japonica   | Korea          | leaf       | 11.9              |
| 19   | Nardostachys jatamansi| Nepal          | root       | 11.7              |
| 20   | Nelumbo nucifera      | Korea          | root       | 16.9              |
| 21   | Patrinia scabiosaefolia| China         | root       | 17.0              |
| 22   | Picrorhiza rhizophora | Nepal          | root       | 38.5              |
| 23   | Piper longum          | Nepal          | fruit      | 13.6              |
| 24   | Pseudostellaria heterophylla| Korea | root       | 21.3             |
| 25   | Rauvolfia serpentina  | Nepal          | root       | 18.0              |
| 26   | Sinapis alba          | China          | seed       | 19.9              |
| 27   | Spaltholobu subercetus| Korea          | stem       | 66.9              |
| 28   | Syzygium aromaticum   | Nepal          | fruit      | 25.5              |
| 29   | Terminalia bellerica  | Nepal          | fruit      | 60.0              |
| 30   | Terminalia chebula    | Nepal          | fruit      | 67.0              |
| 31   | Withania somnifera    | Nepal          | root       | 18.0              |

**Determination of total phenol, flavonoid and antioxidative activity of M. japonica extract and its fractions:** Total phenolic content, flavonoid and antioxidative activity of M. japonica extract and its fractions were determined according to previous experiments. Gallic acid (10 – 500 mg/L) was used for calculation and the results were expressed as mg of gallic acid equivalents (GCE) per g of extract using rutin as a standard. The flavonoid content was calculated from a rutin standard curve and the results were expressed as mg of rutin equivalents per g of extract.

Hydrogen peroxide (H₂O₂) induced cell death: Experiments were carried out 24 hrs after HT22 cells were seeded. For H₂O₂ treatment, the cells were washed with serum free glucose solution. Dilution of H₂O₂ was made from a 30% stock solution into serum free glucose solution just prior to each experiment and 30 µM solution added to the cells. The culture plates were incubated for additional 24 hrs.
Stock solution of each test sample was prepared in DMSO, and the solution was diluted in DMEM solution (with glucose/without glucose) so the final concentration of DMSO did not exceed 0.1% (v/v). Each test samples with different concentrations were treated 30 min before and during OGD exposure. OGD control cells were treated with equal amount of glucose free DMEM solution containing 0.1% DMSO. Normal cells were treated with the equal amounts of serum free glucose solution containing 0.1% DMSO and kept in the normal incubator. For H$_2$O$_2$, samples of different concentrations were treated during H$_2$O$_2$ exposure. Normal cells (without H$_2$O$_2$) were incubated under the same conditions.

Cell survival was evaluated by the ability to reduce MTT to formazan. MTT was dissolved in DMEM and added to the culture at final concentration of 0.5 mg/ml. After additional 2 hrs of incubation at 37°C, the media was carefully removed and 100 µl DMSO added to each well. The optical density (OD) was measured on plate reader (SPECTRA max Plus1 absorb, USA) at 570 nm. Results were expressed as % of the normal cells (untreated cells). All results were presented as mean ± SEM. Significant differences between experimental groups were determined by student’s t test. $P < 0.05$ was considered to indicate statistically significance.

**RESULTS**

**Screening of Plant material against in vitro model of ischemia**

The rate of cell protection and IC$_{50}$ value for NO scavenging activity of each plant extracts are presented in Table 2. In this study, 31 medicinal plants were collected from China, Korea and Nepal and were examined their neuroprotective effects against in vitro ischemia model on neuronal cells. Baicalein was used as a reference for OGD, which showed 30% protection on HT22 cells against OGD-R induced cell death (Fig. 2).

As determined by MTT reduction, H$_2$O$_2$ has dose dependent cytotoxicity effects on HT22 cells. The cells treated with H$_2$O$_2$ (30 µM, 24 h) induced 30% of cell death as compared to the normal group. Viable cells increased from 73.2 ± 3.9% in control group to 87.5 ± 4.1% ($p < 0.05$), 94.5 ± 5.2% ($p < 0.01$) and 89.9 ± 4.2% ($p < 0.05$) in MJEf (0.1, 1 and 10 µg/ml), 89.5 ± 6.1% ($p < 0.05$), 92.82 ± 1.4% ($p < 0.001$) in MJBf (1 and 10 µg/ml) treated cells respectively, however; MJHf didn’t show any significant effect against OGD-R induced cell death (Fig. 1).

**Table 2: Cell protection against OGD-R and LPS, and NO inhibition assay**

| No. | Cell Protection % (a) | Cell Protection % (b) | NO inhibition (IC$_{50}$ µg/mL) |
|-----|-----------------------|-----------------------|----------------------------------|
| Baicalein | 30.0 | -- | -- |
| 1 | 5.4 | 7.4 | 60.5 |
| 2 | (-) | 22.0 | 11.2 |
| 3 | 17.1 | 19.8 | 45.6 |
| 4 | 5.8 | 22.8 | 8.4 |
| 5 | (-) | 5.2 | 34.5 |
| 6 | (-) | (-) | 37.5 |
| 7 | 18.0 | 7.1 | 0.1 |
| 8 | 22.4 | 13.5 | 60.3 |
| 9 | 9.0 | 10.3 | 57.8 |
| 10 | (-) | (-) | (-) |
| 11 | 17.0 | 33.1 | 8.9 |
| 12 | (-) | (-) | 48.5 |
| 13 | 10.8 | 24.3 | 28.4 |
| 14 | (-) | (-) | (-) |
| 15 | 11.9 | 1.4 | 24.6 |
| 16 | 7.2 | 1.3 | 48.0 |
| 17 | (-) | 10.8 | 6.6 |
| 18 | 34.1 | 1.9 | 46.7 |
| 19 | 14.7 | 44.0 | 4.3 |
| 20 | 9.1 | (-) | 80.7 |
| 21 | 26.9 | (-) | (-) |
| 22 | 29.1 | 20.0 | 5.6 |
| 23 | 11.8 | 24.7 | 6.5 |
| 24 | (-) | 10.9 | 53.1 |
| 25 | 26.0 | 24.0 | 6.2 |
| 26 | 6.9 | 10.9 | 54.3 |
| 27 | 8.0 | (-) | 49.4 |
| 28 | 17.5 | 24.8 | 4.8 |
| 29 | 10.6 | 23.0 | <0.1 |
| 30 | 34.9 | 19.0 | <0.1 |
| 31 | 23.9 | 29.9 | 4.3 |
samples at 10 μg/mL protected HT22 cells against OGD induced cell death.

\textsuperscript{b} samples at 10 μg/mL protected BV2 cells against LPS induced cell death.

\textsuperscript{c} IC\textsubscript{50} values in μg/mL, \textsuperscript{d} mg GAE/g extract, \textsuperscript{e} mg RE/g extract

\textbf{DISCUSSION}

Over the past few decades, many researchers have attempted to develop anti-neurotoxin agents that are capable of preventing the release of glutamate, activation of microglia, oxidative stress, Ca\textsuperscript{2+} influx, apoptosis, and cell cycle arrest.\textsuperscript{7,8,13-15} Although many reagents, such as glutamate receptor antagonists, Ca\textsuperscript{2+} channel blockers, anti-inflammatory agents, and NOS inhibitors, have shown neuroprotective effects, their serious side effects have limited their clinical application. Therefore, researchers searched for novel plant extracts/compounds with better neuroprotective effects and fewer side effects. The greater potency of the novel compounds and their effectiveness against ischemia and various neurodegenerative diseases has generated a great deal of excitement among neuroscientists, medicinal chemists, and clinicians.

Thus, to search the effective neuroprotective plants, different plants extract were screened against \textit{in vitro} ischemia model. From the results of screening test, \textit{Metaplexis japonica} was selected for further study. \textit{M. japonica} was further extracted and fractionated by different organic solvents and the neuroprotective effect of MJC and its fractions \textit{in vitro} ischemia model induced by OGD-R was evaluated. For oxidative stress model, H\textsubscript{2}O\textsubscript{2} induced cell death was observed in HT22 cells. MJC, MJEf and MJBf significantly reduced the HT22 cell damage, which was induced by 4 hrs of OGD followed by 24 hrs of reoxygenation and 24 hrs of H\textsubscript{2}O\textsubscript{2} respectively. Exposure of HT22 cells to 4 h of OGD followed by 24 hrs of reoxygenation decreased in cell viability as compared to normal cells; whereas treatment of MJC and its fractions at 1 and 10 μg/ml concentration increased neuronal cell viability as compared to control group. MJC reduced cell damage by 20% at 10 μg/ml whereas the activity of MJEf and MJBf was found to be higher than that of extract; however MJHF could not show significant effect against OGD-R. The efficacy of MJEf at 1 μg/ml was 44% but at higher concentration it showed lower activity. Likewise, the efficacy of MJBf was 39% and 37% at 1 and 10 μg/ml concentrations, respectively.

The OGD assay is a powerful tool for screening of substances for treatment or prevention of ischemia related diseases. As OGD mimics tissue ischemia, it resulted in the production of ROS, release from glutamate toxicity, and inflammatory cytokines.\textsuperscript{1,6} The compounds/plants extract having antioxidative, anti-inflammatory or glutamate antagonist property may protect the neuronal cells OGD-R induced cell death. In order to know the effects of MJC and its fractions against oxidative stress, H\textsubscript{2}O\textsubscript{2} was treated to HT22 cells. H\textsubscript{2}O\textsubscript{2} is believed to be the major precursor for highly reactive free radicals, and has been reported to induce cell apoptosis in the central nervous system. In the current study, we found that H\textsubscript{2}O\textsubscript{2} has dose-dependently and time-dependently toxic to cells (data not shown) whereas treatment of MJC, MJEf and MJBf decreased cell death in a dose-dependent manner (Fig 2). The maximum effect of MJC, MJEf and MJBf...
against H$_2$O$_2$-induced neurotoxicity was observed at the concentration of 10 μg/ml where as MJHF could not show significant effects. The activity was found in the order of MJEF > MJBF > MJC which is similar with in vitro ischemia (OGD) which indicate that protective activity of samples against OGD-R and H$_2$O$_2$ induced cell death may related with their antioxidative activity. Further, we examined the effects of MJC and fractions against DPPH free radical scavenging activity, and we found that activity of MJEF and MJBF were higher than MJC, where as MJHF shows very weak activity. According to in vitro results (OGD-R, H$_2$O$_2$) it is hypothesized that MJC, MJEF and MJBF could prevent ischemia-induced brain damage in in vivo system.

**CONCLUSION**

MJC and its fractions showed a neuroprotective effect in vitro ischemia. The effectiveness of MJEF was higher than other fractions/crude extract which indicate that the neuroprotective agent of MJC may partitioned to MJE fraction. Further study is necessary to isolate the neuroprotective compounds from MJC and their mechanisms of action.

**REFERENCES**

1. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999; (79):1431-1568.
2. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. Neuro Res. 2004; (1):36-45.
3. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study, Stroke. 2004; 357:731-735.
4. Hankey GJ, Spiessier J, Hakimi Z, Bego G, Carita P, Gabriel S. Rate, degree, and predictors of recovery from disability following ischemic stroke. Neurology. 2007; 68(19):1583-1587.
5. Clemens JA. Cerebral ischemia: gene activation, neuronal injury, and the protective role of antioxidants. Free Radic Biol Med. 2000; (28):1526-1531.
6. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999; (22):391-397.
7. Kim H. Neuroprotective herbs for stroke therapy in traditional eastern medicine. Neurol Res. 2005; (27):287-301.
8. Ginsberg MD. Neuroprotection for ischemic stroke: Past, present and future. Neuropharm. 2008; 55(3):363-89.
9. Bu Y, Rho S, Kim J, Kim MY, Lee DH, Kim SY, Choi H, Kim H. Neuroprotective effect of tyrosol on transient focal cerebral ischemia in rats. Neurosci Lett. 2007; (414):218-221.
10. Brueur U, Weih MK, Isaev NK, Meisel A, Ruchser K, Bergk A, Trendelenburg G, Wiegand F, Victorov IV, Dirnagl U. Induction of tolerance in rat cortical neurons: hypoxic preconditioning. FEBS Lett. 1997; (414):117-121.
11. Jamarkattel-Pandit N, Pandit NR, Baral KP, Kim H. Cytoprotective effect of Terminalia chebula Retz against Oxygen-Glucose deprivation on rat pheochromocytoma call. JHAS. 2012; (2):1-6.
12. Parajuli S, Pun NT, Parajuli S, Jamarkattel-Pandit N. Antioxidant Activity, total Phenol and Flavanoid Content of some selected Medicinal Plants of Nepal. JHAS. 2012; (2):27-31.
13. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies-the need for new approaches. Cerebrovasc Dis. 2004; (17 Suppl 1): 153-166.
14. Danton G H, Dietrich WD. The search for neuroprotective strategies in stroke. AJNR Am J Neuroradiol. 2004; (25):181-194.
15. Sucher, NJ. Insights from molecular investigations of traditional Chinese herbal stroke medicines: Implications for neuroprotective epilepsy therapy. Epilepsy Behav. 2006; 8:350-362.
16. Bruno VM, Goldberg MP, Dugan L L, Giffard RG, Choi DW. Neuroprotective effect of hypothermia in cortical cultures exposed to oxygen-glucose deprivation or excitatory amino acids. J Neurochem. 1994; (63):1398-1406.